



Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference

February 20, 2019

GERMANTOWN, Md., Feb. 20, 2019 /PRNewswire/ -- [Intrexon Corporation](#) (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned subsidiary [Precigen, Inc.](#), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced their presentation at the SVB Leerink 8th Annual Global Healthcare Conference in New York. Helen Sabzevari, PhD, president of Precigen, will present on Thursday, February 28, 2019 at 11:30 am Eastern Time.

Investors, analysts, media and other interested parties may participate in the event at 11:30 am Eastern Time via live audio webcast, which can be accessed through Intrexon's website in the Investors section under 'Events' at [investors.dna.com/events](#) and on Precigen's website under 'Presentations' at [www.precigen.com/media/#id-presentations](#). The presentation will be archived on the Intrexon and Precigen websites following the presentation.

About Intrexon Corporation

Intrexon Corporation (NASDAQ:XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA® and we invite you to discover more at [www.dna.com](#) or follow us on Twitter at [@Intrexon](#), on [Facebook](#), and [LinkedIn](#).

Precigen : Advancing Medicine with Precision™

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen also follows the science opportunistically in pursuit of promising programs in emerging therapeutics. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. Precigen was founded as a wholly-owned subsidiary of [Intrexon Corporation](#) (NASDAQ: XON) and leverages Intrexon's proprietary technology platforms to advance human health. For more information about Precigen, visit [www.precigen.com](#) or follow us on Twitter [@Precigen](#) and [LinkedIn](#).

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to plans, objectives and expectations for the development of our business, including the timing and progress of preclinical and clinical trials and discovery programs. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

Intrexon Investor Contact:

Steven Harasym

Vice President, Investor Relations

Tel: +1 (214) 721-0607

investors@dna.com

Intrexon Corporate Contact:

Marie Rossi, PhD

Vice President, Communications

Tel: +1 (301) 556-9850

publicrelations@dna.com

Precigen Media Contact:

Donelle M. Gregory

press@precigen.com

SOURCE Intrexon Corporation; Precigen, Inc.